KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.90

Randomized Study of Metformin and Intensive Lifestyle Intervention on Cancer Incidence over 21 Years of Follow-up in the Diabetes Prevention Program.

Brandy M Heckman-Stoddard, Jill P Crandall, Sharon L Edelstein, Philip C Prorok, Dana Dabelea, Richard Hamman, Helen P Hazuda, Edward Horton, Mary A Hoskin, Marjorie Perloff, Anna Bowers, William C Knowler, Leslie G Ford, Marinella Temprosa, DPP Research Group

Cancer Prev Res (Phila) 18(7) 401-411

PMID40243198
PMCIDPMC12213222
DOI10.1158/1940-6207.CAPR-23-0461
发表日期2025-04-17
入排依据:The study is a Phase III randomized trial with a drug intervention and a time-to-event primary endpoint (cancer incidence, reported with HR). However, it is not an oncology trial for human malignant neoplasm; it is a primary prevention study in a diabetes population where cancer incidence is a safety or secondary outcome, not a treatment efficacy endpoint for an existing malignancy. Therefore, it does not meet the specific oncology cohort inclusion criteria.
已检查 4 张 PubMed Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:AI 判定为 other;Figure 3:AI 判定为 other;Figure 4:森林图/亚组分析图。
摘要

摘要

UNLABELLED: Meta-analyses have reported a decrease in overall cancer incidence of approximately 10% to 40% with metformin use among individuals with diabetes. Lifestyle change could potentially reduce cancer incidence. The objective was to determine whether metformin or intensive lifestyle (ILS) intervention reduces the risk of cancer among adults at high risk of diabetes. The Diabetes Prevention Program (1996-2001) randomized 3,234 participants to ILS, metformin (850 mg twice daily), or blinded placebo. During follow-up through the Diabetes Prevention Program Outcomes Study, all participants were offered a modified lifestyle intervention, and metformin continued in an open-label metformin group. Participants reported cancer cases annually. Medical records were adjudicated for all reported events. The primary endpoint was total cancer incidence, comparing metformin versus placebo, with ILS versus placebo as a secondary objective. After a median follow-up of 21 years, 546 participants (173 metformin, 182 ILS, and 191 placebo) were diagnosed with a first incident cancer. Incidence rates of cancer were 9.8, 10.5, and 10.8 per 1,000 person-years in metformin, ILS, and placebo, respectively, with a HR of 0.90 (95% confidence interval, 0.73-1.10) for metformin compared with placebo and 0.96 (95% confidence interval, 0.79-1.18) for ILS compared with placebo. There were no differences between any treatment groups for obesity-related cancer or in sex-specific analyses. Neither assignment to metformin nor ILS reduced cancer incidence among adults at high risk of diabetes. These results may be impacted by increased nonstudy metformin usage over time due to the development of diabetes and reduced intensity of the ILS intervention over time. PREVENTION RELEVANCE: This study examines both metformin and ILS intervention as primary cancer prevention interventions in people at high risk for type 2 diabetes.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(4,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1. Consort Flow Chart for the Diabetes Prevention Program Outcomes Study The consort flow depicts the course of participants since original randomization in DPP to Placebo, Metformin or Lifestyle, enrollment in the Diabetes Prevention Program Outcomes Study, analytic cohort and participant status through various phases of DPPOS.
非 KM Figure
Figure 2Figure 2. Total and Study Metformin use, Weight and Physical Activity Changes by Original Randomized Group During Follow-up (A) Cumulative metformin which includes both study and out of study use. (B) Proportion of participants taking any study metformin and use at least 80% of study metformin in participants randomized to metformin and eligible to have study metformin. By protocol, participants are no longer eligible to take study metformin when fasting glucose exceeds 140 mg/dl or more in DPP or HbA1c exceeds 7% or more in DPPOS. Participants who are no longer eligible were taken off study metformin and management referred to their primary care provider. (C) Mean weight (kg) during follow-up. (D) Median leisure physical activity is based on the MAQ.
非 KM Figure
Figure 3Figure 3. Cumulative Incidence for Total (A), Obesity (B), and Non-obesity (C) Cancer by Original Treatment Group First incident cancer was used in each of the three panels. Obesity-related cancer was defined as meningioma, multiple myeloma, or cancer of the esophagus, kidneys, uterus, ovaries, thyroid, breast (postmenopausal), liver, gallbladder, upper stomach, pancreas, colon, and rectum. The remainder of cancer types were considered as nonobesity-related.
非 KM Figure
Figure 4Figure 4. Effect of Metformin versus Placebo (A) and Lifestyle versus Placebo (B) on Total Cancer Incidence by Subgroups Treatment effects by pre-defined subgroups are expressed as hazard ratio (95% confidence interval) with heterogeneity p-value assessed using interaction of subgroup x original randomized groups. All subgroups were assessed at baseline except for diabetes status which was a time varying subgroup.
非 KM Figure